Microbot Medical Inc. (MBOT)
NasdaqCM · Price as of · Delayed Quote
- Profitability0/20
Losing money: $-16.3M net income over the last four reported quarters.
- Insider buying vs selling12/20
The last 10 Form 4s show no open-market buys or sells (grants and option exercises don't count either way). Neutral.
- Dilution and offerings1/15
Share count up 47.5% in a year and 7 offering-related filings. Heavy dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.
- Analysts3
- Implied upside+359.8%
- Target range$4.00 to $12.00
MBOT closed at $1.45 on Sep 11, down 16.7% since Aug 12. Chart read: price below both the 50-day and 200-day moving averages; the 50-day is below the 200-day (downtrend structure); trading at 0% of the 52-week range ($1.44 to $4.05).
SEC filings
| Form | Filed | Description |
|---|---|---|
| 8-K | August 11, 2026 | 8-K |
| 10-Q | August 11, 2026 | 10-Q |
| 8-K | August 7, 2026 | 8-K |
| 8-K | July 21, 2026 | 8-K |
| 8-K | July 7, 2026 | 8-K |
| 8-K | June 30, 2026 | 8-K |
| 8-K | June 25, 2026 | 8-K |
| 8-K | June 23, 2026 | 8-K |
Frequently asked questions
What do analysts expect for MBOT?
3 analysts cover Microbot Medical Inc. (MBOT). No consensus rating has been published. The average price target is $6.67, in a range of $4.00 to $12.00.
Are insiders buying or selling MBOT?
We have no qualifying Form 4 insider purchases or sales on record for Microbot Medical Inc. (MBOT). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see MBOT SEC filings?
Recent filings are listed on this page, newest first. The latest is an 8-K filed August 11, 2026.